Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: gamesmistress who wrote (2948)	6/11/1998 10:17:00 PM
From: Quad Sevens	Read Replies (1) \| Respond to of 5736

It was all a misunderstanding: Asensio thought CCSI was addressing the "non-evasive bilirubin market". Wade

To: gamesmistress who wrote (2948)	6/11/1998 10:25:00 PM
From: Roger A. Babb	Read Replies (3) \| Respond to of 5736

Gina, CCSI pointed out the fact that they expect to make most of their revenues from the "disposable device", not the sale of the instrument, in their rebuttal. By implication, they must expect to sell it for upwards of $20 to meet their $300 million market projection. If the procedure is non-invasive, I have some trouble visualizing a component that can not be reused unless it is somehow contaminated, damaged, or used up in the process. Also disposable medical supplies tend to be bought cheap on competitive bids. Can anyone comment on this? Also I think it is misleading to count 90% of all the babies born worldwide as the market. I venture to say that a substantial portion of births take place with no medical care involved and $20 would be financially out of reach for the family to spend on a test procedure, whether or not needed. Obviously the good doctor making that statement has never worked in the 3rd world where a majority of the world's babies are being born.